Attached files

file filename
EX-31.2 - CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302 - ZOGENIX, INC.ex312-2014331.htm
XML - IDEA: XBRL DOCUMENT - ZOGENIX, INC.R10.htm
10-Q - 10-Q - ZOGENIX, INC.zgnx-2014331x10q.htm
XML - IDEA: XBRL DOCUMENT - ZOGENIX, INC.R20.htm
XML - IDEA: XBRL DOCUMENT - ZOGENIX, INC.R27.htm
XML - IDEA: XBRL DOCUMENT - ZOGENIX, INC.R5.htm
XML - IDEA: XBRL DOCUMENT - ZOGENIX, INC.R26.htm
XML - IDEA: XBRL DOCUMENT - ZOGENIX, INC.R21.htm
XML - IDEA: XBRL DOCUMENT - ZOGENIX, INC.R16.htm
XML - IDEA: XBRL DOCUMENT - ZOGENIX, INC.R14.htm
XML - IDEA: XBRL DOCUMENT - ZOGENIX, INC.R15.htm
XML - IDEA: XBRL DOCUMENT - ZOGENIX, INC.R19.htm
XML - IDEA: XBRL DOCUMENT - ZOGENIX, INC.R23.htm
XML - IDEA: XBRL DOCUMENT - ZOGENIX, INC.R11.htm
XML - IDEA: XBRL DOCUMENT - ZOGENIX, INC.R12.htm
XML - IDEA: XBRL DOCUMENT - ZOGENIX, INC.R4.htm
XML - IDEA: XBRL DOCUMENT - ZOGENIX, INC.R18.htm
XML - IDEA: XBRL DOCUMENT - ZOGENIX, INC.R1.htm
XML - IDEA: XBRL DOCUMENT - ZOGENIX, INC.R17.htm
XML - IDEA: XBRL DOCUMENT - ZOGENIX, INC.R3.htm
XML - IDEA: XBRL DOCUMENT - ZOGENIX, INC.R7.htm
XML - IDEA: XBRL DOCUMENT - ZOGENIX, INC.R24.htm
XML - IDEA: XBRL DOCUMENT - ZOGENIX, INC.R22.htm
XML - IDEA: XBRL DOCUMENT - ZOGENIX, INC.R6.htm
XML - IDEA: XBRL DOCUMENT - ZOGENIX, INC.R2.htm
XML - IDEA: XBRL DOCUMENT - ZOGENIX, INC.R8.htm
XML - IDEA: XBRL DOCUMENT - ZOGENIX, INC.R28.htm
XML - IDEA: XBRL DOCUMENT - ZOGENIX, INC.R29.htm
EXCEL - IDEA: XBRL DOCUMENT - ZOGENIX, INC.Financial_Report.xls
XML - IDEA: XBRL DOCUMENT - ZOGENIX, INC.R9.htm
XML - IDEA: XBRL DOCUMENT - ZOGENIX, INC.R25.htm
EX-32.2 - CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 906 - ZOGENIX, INC.ex322-2014331.htm
EX-32.1 - CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 906 - ZOGENIX, INC.ex321-2014331.htm
EX-31.1 - CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 - ZOGENIX, INC.ex311-2014331.htm
EX-10.3 - INDEPENDENT DIRECTOR COMPENSATION POLICY AMENDED MARCH 2014 - ZOGENIX, INC.ex103directorcomppolicyres.htm
EX-10.2 - AMENDMENT 1 TO ALTUS DEVELOPMENT & OPTION AGREEMENT - ZOGENIX, INC.ex102amend1toaltusdoagrmt.htm
EX-10.1 - MALLINCKRODT CO-PROMOTION TERMINATION AGREEMENT - ZOGENIX, INC.ex101mallinckrodtterminati.htm
v2.4.0.8
Summary of Significant Accounting Policies (Policies)
3 Months Ended
Mar. 31, 2014
Accounting Policies [Abstract]  
Financial Statement Preparation and Use of Estimates
Financial Statement Preparation and Use of Estimates
The unaudited consolidated financial statements contained in this Quarterly Report on Form 10-Q have been prepared by Zogenix, Inc. according to the rules and regulations of the Securities and Exchange Commission (SEC) and, therefore, certain information and disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles (GAAP) have been omitted.
In the opinion of management, the accompanying unaudited consolidated financial statements for the periods presented reflect all adjustments, which are normal and recurring, necessary to fairly state the financial position, results of operations and cash flows. These unaudited consolidated financial statements should be read in conjunction with the audited financial statements included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2013 filed with the SEC on March 7, 2014.
The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results may differ from those estimates.
Principles of Consolidation
Principles of Consolidation
The unaudited interim consolidated financial statements include the accounts of Zogenix, Inc. and its wholly owned subsidiary Zogenix Europe Limited, which was incorporated under the laws of England and Wales in June 2010. All intercompany transactions and investments have been eliminated in consolidation. Zogenix Europe Limited’s functional currency is the U.S. dollar, the reporting currency of its parent.
Fair Value Measurements
Fair Value Measurements
The carrying amount of financial instruments consisting of cash, trade accounts receivable, prepaid expenses and other current assets, accounts payable, accrued expenses, accrued compensation and current portion of long-term debt included in the Company’s consolidated financial statements are reasonable estimates of fair value due to their short maturities. Based on the borrowing rates currently available to the Company for loans with similar terms, management believes the fair value of long-term debt approximates its carrying value. The accrued liability for the annual tail payment due to Astellas Pharma US, Inc. (Astellas) (see Note 4) for the termination of the Company’s co-promotion agreement was measured at fair value in December 2011 using a present value technique, which incorporated the Company’s own credit risk as measured by the most recent round of debt financing with Healthcare Royalty Partners (Healthcare Royalty) (formerly Cowen Healthcare Royalty Partners II, L.P.).
Authoritative guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:
 
Level 1:
Observable inputs such as quoted prices in active markets;
Level 2:
Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and
Level 3:
Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.

The Company classifies its cash equivalents within Level 1 of the fair value hierarchy because it values its cash equivalents using quoted market prices. The Company classifies its common stock warrant liabilities and embedded derivative liabilities within Level 3 of the fair value hierarchy because they are valued using valuation models with significant unobservable inputs.
Changes in fair value of the liabilities shown in the table above are recorded through change in fair value of warrant liabilities and change in fair value of embedded derivatives in other income (expense) in the consolidated statements of operations and comprehensive loss.
Net Loss per Share
Net Loss per Share
Basic net loss per share is calculated by dividing the net loss by the weighted average number of common shares outstanding for the period, reduced by weighted average shares subject to repurchase, without consideration for common stock equivalents. Diluted net loss per share is computed by dividing the net loss by the weighted average number of common share equivalents outstanding for the period determined using the treasury-stock method and as-if converted method, as applicable. For purposes of this calculation, stock options, restricted stock units and warrants are considered to be common stock equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive.
Revenue Recognition
Revenue Recognition
The Company recognizes revenue from the sale of Sumavel DosePro, Zohydro ER and from license fees, milestones and service fees earned on collaborative arrangements. Revenue is recognized when (i) persuasive evidence of an arrangement exists, (ii) delivery has occurred and title has passed, (iii) the price is fixed or determinable and (iv) collectability is reasonably assured. Revenue from sales transactions where the buyer has the right to return the product is recognized at the time of sale only if (a) the Company’s price to the buyer is substantially fixed or determinable at the date of sale, (b) the buyer has paid the Company, or the buyer is obligated to pay the Company and the obligation is not contingent on resale of the product, (c) the buyer’s obligation to the Company would not be changed in the event of theft or physical destruction or damage of the product, (d) the buyer acquiring the product for resale has economic substance apart from that provided by the Company, (e) the Company does not have significant obligations for future performance to directly bring about resale of the product by the buyer, and (f) the amount of future returns can be reasonably estimated. The Company currently defers recognition of revenue on product shipments of Zohydro ER until the right of return no longer exists, as the Company currently cannot reliably estimate expected returns of the product at the time of shipment given the limited sales history of Zohydro ER.

Product Revenue, Net
The Company sells Sumavel DosePro and Zohydro ER in the United States to wholesale pharmaceutical distributors and retail pharmacies, or collectively the Company's customers, subject to rights of return within a period beginning six months prior to, and ending 12 months following, product expiration. The Company recognizes Sumavel DosePro product sales at the time title transfers to its customer, and reduces product sales for estimated future product returns and sales allowances in the same period the related revenue is recognized.
Given the limited sales history of Zohydro ER, the Company cannot reliably estimate expected returns of the product at the time of shipment. Accordingly, the Company defers recognition of revenue on Zohydro ER product shipments until the right of return no longer exists, which occurs at the earlier of the time Zohydro ER is dispensed through patient prescriptions or expiration of the right of return. The Company estimates Zohydro ER patient prescriptions dispensed using an analysis of third-party syndicated data. Zohydro ER was launched in March 2014 and, accordingly, the Company does not have significant history estimating the number of patient prescriptions dispensed. If the Company underestimates or overestimates patient prescriptions dispensed for a given period, adjustments to revenue may be necessary in future periods. The deferred revenue balance does not have a direct correlation with future revenue recognition as the Company will record sales deductions at the time the prescription unit is dispensed.
The Company will continue to recognize Zohydro ER revenue upon the earlier to occur of prescription units dispensed or expiration of the right of return until it can reliably estimate product returns, at which time the Company will record a one-time increase in revenue related to the recognition of revenue previously deferred, net of estimated future product returns and sales allowances. In addition, the costs of Zohydro ER associated with the deferred revenue are recorded as deferred costs, which are included in inventory, until such time the related deferred revenue is recognized.
Product sales allowances for Sumavel DosePro and Zohydro ER include wholesaler and retail pharmacy distribution fees, prompt pay discounts, chargebacks, rebates and patient discount programs, and are based on amounts owed or to be claimed on the related sales. These estimates take into consideration the terms of the Company's agreements with its customers and third-party payors and the levels of inventory within the distribution and retail channels that may result in future rebates or discounts taken. In certain cases, such as patient support programs, the Company recognizes the cost of patient discounts as a reduction of revenue based on estimated utilization. If actual future results vary, the Company may need to adjust these estimates, which could have an effect on product revenue in the period of adjustment. The Company records product sales deductions in the statement of operations at the time product revenue is recognized.
Segment Reporting
Segment Reporting
Management has determined that the Company operates in one business segment, which is the development and commercialization of pharmaceutical products for people living with pain-related conditions and central nervous system disorders.
Recent Accounting Pronouncements
Recent Accounting Pronouncements
In April 2014, the Financial Accounting Standards Board issued an accounting update that raises the threshold for disposals to qualify as discontinued operations and allows companies to have significant continuing involvement with and continuing cash flows from or to the discontinued operations. This accounting update also requires additional disclosures for discontinued operations and new disclosures for individually material disposal transactions that do not meet the definition of a discontinued operation. This guidance will be effective for fiscal years beginning after December 15, 2014, with early adoption permitted. The Company does not expect that the adoption of the guidance will have a material impact on the Company's financial statements.